# Designing and evaluating the acceptability of a psychosocial and socioeconomic support package for people with drug-resistant tuberculosis in Johannesburg, South Africa

**Authors:** Ndiviwe Mphothulo, Marian Loveday

PMC · DOI: 10.1371/journal.pone.0343154 · PLOS One · 2026-03-03

## TL;DR

This study created and tested a support package for people with drug-resistant tuberculosis in South Africa to help with psychosocial and socioeconomic challenges.

## Contribution

A novel psychosocial and socioeconomic support package for DR-TB patients was developed and found acceptable by users.

## Key findings

- The support package was developed using input from DR-TB patients, family members, and stakeholders.
- Successfully treated DR-TB patients and their families found the intervention acceptable.
- The package is believed to reduce barriers to retention in care during treatment.

## Abstract

Drug-resistant tuberculosis (DR-TB) is a global health problem that presents multifaceted challenges to people living with the disease. These challenges lead to sub-optimal adherence in some DR-TB patients who are then not cured of their TB. Besides the challenges associated with taking treatment, many patients with DR-TB also have to contend with psychosocial and socioeconomic challenges. The objective of this study was to develop a psychosocial and socioeconomic intervention for people with DR-TB in Johannesburg, South Africa, and evaluate if they find it acceptable. Guided by the Behaviour Change Wheel (BCW) and Perceptions and Practicalities Approach (PaPA) frameworks, and utilising a participatory research approach, We developed a support package with input from a qualitative needs assessment with DR-TB patients (n = 16) and family members (n = 8) and input from various stakeholders (n = 18), (health managers, clinicians and officials from social security departments). The support package was then evaluated for acceptability by patients who had successfully completed DR-TB treatment (n = 13) and their families (n = 6), using an exploratory qualitative method. Both successfully treated DR-TB patients and their family members found the intervention to be acceptable and believed it will reduce the barriers to retention in care that they faced during their treatment journey.

## Linked entities

- **Diseases:** drug-resistant tuberculosis (MONDO:0041806), TB (MONDO:0018076)

## Full-text entities

- **Diseases:** SSIs (MESH:D020914), DR-TB.2 (MESH:D018088), SASSA (MESH:D046350), TB (MESH:D014390), DS-TB (MESH:D014376), DSD (OMIM:300082), Extreme Drug Resistant TB (MESH:D054908), DR- (MESH:D004370), discrimination (MESH:D010468)
- **Chemicals:** isoniazid (MESH:D007538), Rifampicin (MESH:D012293), linezolid (MESH:D000069349), FDG (MESH:D019788), fluoroquinolone (MESH:D024841), bedaqualine (-)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mycobacterium tuberculosis (species) [taxon 1773]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12956097/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12956097/full.md

## References

30 references — full list in the complete paper: https://tomesphere.com/paper/PMC12956097/full.md

---
Source: https://tomesphere.com/paper/PMC12956097